About Abpro Corporation
https://abpro.comAbpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry.
CEO
Jin Wook Suk
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public March 9, 2022
Full time employees 6
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-11-03 | Reverse | 1:30 |
ETFs Holding This Stock
Summary
Total 1
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Discounted Cash Flow 1
Return On Equity 5
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Hold 1
Showing Top 1 of 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $8.23 M
52w High $42.90
52w Low $3.78
P/E -0.47
Volume 24.64K
Outstanding Shares 2.03M
About Abpro Corporation
https://abpro.comAbpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $1.2M ▼ | $-1.66M ▲ | 0% | $-0.63 ▲ | $-1.32M ▲ |
| Q2-2025 | $0 | $2.26M ▼ | $-2.98M ▲ | 0% | $-1.56 ▲ | $-2.67M ▲ |
| Q1-2025 | $0 ▼ | $2.96M ▼ | $-3.89M ▲ | 0% ▲ | $-2.4 ▲ | $-3M ▲ |
| Q4-2024 | $183K ▲ | $8.18M ▲ | $-5.51M ▼ | -3.01K% ▼ | $-17.7 ▼ | $-5.18M ▼ |
| Q3-2024 | $0 | $391.69K | $-335K | 0% | $-1.07 | $-299K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $343K ▼ | $1.7M ▼ | $17.3M ▼ | $-16.14M ▲ |
| Q2-2025 | $2.01M ▲ | $3.48M ▲ | $20.43M ▼ | $-17.5M ▲ |
| Q1-2025 | $1.26M ▼ | $2.8M ▼ | $20.61M ▲ | $-18.36M ▼ |
| Q4-2024 | $2.85M ▲ | $4.66M ▼ | $19.61M ▲ | $-15.49M ▼ |
| Q3-2024 | $13.6K | $7.86M | $19.54M | $-11.68M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.66M ▲ | $-2.28M ▼ | $26K ▲ | $569K ▼ | $-1.69M ▼ | $-2.28M ▼ |
| Q2-2025 | $-2.98M ▲ | $-1.39M ▲ | $0 | $2.01M ▲ | $624K ▲ | $-1.39M ▲ |
| Q1-2025 | $-3.89M ▲ | $-1.72M ▲ | $0 ▲ | $132K ▼ | $-1.59M ▼ | $-1.72M ▲ |
| Q4-2024 | $-5.51M ▼ | $-8.25M ▼ | $-29.64M ▼ | $40.27M ▲ | $2.98M ▲ | $-8.25M ▼ |
| Q3-2024 | $81.33K | $3.44M | $0 | $936K | $-188.4K | $3.44M |
CEO
Jin Wook Suk
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public March 9, 2022
Full time employees 6
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-11-03 | Reverse | 1:30 |
ETFs Holding This Stock
Summary
Total 1
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Discounted Cash Flow 1
Return On Equity 5
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Hold 1
Showing Top 1 of 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0